Overview

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Status:
Recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks

Phase:

Phase 3

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.